Congestive Heart Failure Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Congestive Heart Failure (CHF) Treatment Devices Market by Product (Ventricular Assist Devices (VADs) [LVAD, RVAD, and BiVAD], Implantable Cardioverter Defibrillators [Transvenous ICD and Subcutaneous ICD], Pacemakers [Implantable and External], Cardiac Resynchronization Therapy [Cardiac Resynchronization Therapy-Defibrillators (CRT-D), and Cardiac Resynchronization Therapy-Pacemakers (CRT-P)], and Others), End-User (Hospitals, Cardiac Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing cases of cardiovascular disorders and the rising product developmental activities worldwide

The congestive heart failure (CHF) treatment devices market was valued at USD 17.41 billion in 2023, growing at a CAGR of 8.26% during the forecast period from 2024 to 2030 to reach USD 27.96 billion by 2030. The congestive heart failure (CHF) treatment devices market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), innovative product developmental activities by regulatory bodies, and the rising geriatric population that is expected to escalate the overall growth of the congestive heart failure (CHF) treatment devices market during the forecast period from 2024 to 2030.

Congestive Heart Failure (CHF) Treatment Devices Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021 it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to the updated data provided by the American Heart Association (2023), it is estimated that by 2030, over 12 million people will have atrial fibrillation globally. According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are currently living with CAD around the world.

Since the prevalence of cardiovascular diseases is increasing, the adoption of congestive heart failure (CHF) treatment devices is playing a critical role in restoring synchronous cardiac function and is hence increasing the market for the same.

Increased product developmental activities by regulatory bodies worldwide is also slated to witness market growth for congestive heart failure (CHF) treatment devices. For example, in January 2024, Element Science received a CE mark in Europe and approval in the U.K. for its patch-based cardioverter defibrillator, designed to offer a more wearable option for individuals at risk of sudden cardiac arrest who may not qualify for or prefer not to have a long-term implant.

As per data provided by the World Health Organization 2021, between 2015 and 2050, people falling between 60 years and above will be doubled from 12 to 22%, and will eventually reach 2.1 billion by the year 2050, globally. Moreover, by 2030, 1 in 6 people will age 60 years or above. As the global population ages, with a significant increase in individuals over 60 years old, who are more susceptible to cardiac events, congestive heart failure (CHF) treatment devices play a vital role in emergency medical care.

Therefore, all the factors stated above collectively will drive the overall congestive heart failure (CHF) treatment devices market growth.

However, stringent regulatory approval process, complications associated with these devices, and others may prove to be challenging factors for the congestive heart failure (CHF) treatment devices market growth.

Congestive Heart Failure (CHF) Treatment Devices Market Segment Analysis:

Congestive Heart Failure (CHF) Treatment Devices Market by Product (Ventricular Assist Devices (VADs) [LVAD, RVAD, and BiVAD], Implantable Cardioverter Defibrillators [Transvenous ICD and Subcutaneous ICD], Pacemakers [Implantable and External], Cardiac Resynchronization Therapy [Cardiac Resynchronization Therapy-Defibrillators (CRT-D), and Cardiac Resynchronization Therapy-Pacemakers (CRT-P)], and Others), End-User (Hospitals, Cardiac Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of congestive heart failure (CHF) treatment devices, the CRT-defibrillators sub-category is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various key features of CRT-defibrillators that enhance their utility and effectiveness.

The ability of CRT-defibrillators to work in multiple indications such as heart failure, arrhythmias as well as sudden cardiac arrest increases its demand. CRT-D devices are equipped with an in-built implantable cardioverter defibrillator besides the biventricular pacemaker component. Thus, the combined CRT-D device functions as a pacemaker in establishing normal heart rhythm along with delivering short electrical impulses to the heart ventricles to establish synchronous contraction. Moreover, CRT-D devices can deliver defibrillation signals in order to disrupt arrhythmias that may lead to sudden cardiac arrest.

Additionally, in October 2023, Medtronic received FDA approval for its Aurora EV-ICD(TM) MRI SureScan extravascular implantable cardioverter-defibrillator and Epsila EV MRI SureScan(TM) defibrillation lead. These devices are designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest.

Therefore, the widespread uses and various key features of CRT-defibrillators that enhance performance and usability coupled with the introduction of new and innovative products are solidifying the impact on the growth of the overall congestive heart failure (CHF) treatment devices market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall congestive heart failure (CHF) treatment devices market:

Among all the regions, North America is expected to dominate the congestive heart failure (CHF) treatment devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the congestive heart failure (CHF) treatment devices market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure, among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of the Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for congestive heart failure (CHF) treatment devices.

Product developmental activities initiated by regulatory bodies will further boost the market for these devices. For example, in June 2024, Elutia Inc., a pioneer in drug-eluting biomatrix products, announced that Antibiotic-Eluting BioEnvelope, EluPro (previously known as CanGaroo during development), received clearance from the U.S. Food and Drug Administration (FDA). Designed to prevent post-operative complications for devices like implantable pacemakers and defibrillators, EluPro integrated potent antibiotic therapy with advanced tissue engineering.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional congestive heart failure (CHF) treatment devices market growth. The presence of key players such as Abbott, Medtronic, and Boston Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America congestive heart failure (CHF) treatment devices market.

Congestive Heart Failure (CHF) Treatment Devices Market key players:

Some of the key market players operating in the congestive heart failure (CHF) treatment devices market include GE HealthCare, Boston Scientific Corporation, Medtronic, Abbott, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.

Recent Developmental Activities in the Congestive Heart Failure (CHF) Treatment Devices Market:

• In October 2024, Abbott a global healthcare leader, announced a new clinical trial, TEAM-HF, designed to improve outcomes for patients with worsening heart failure. The first-of-its-kind trial will leverage AI and Abbott's CardioMEMS(TM) HF System to identify patients who may benefit from earlier intervention with advanced therapies, such as a HeartMate 3(TM) left ventricular assist device (LVAD).
• In June 2021, Medtronic launched the world's smallest pacemaker to treat heart block. Micra AV with atrioventricular synchrony is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart. The in-house created pacemaker is small enough to go inside the heart via a catheter.

Key Takeaways from the Congestive Heart Failure (CHF) Treatment Devices Market Report Study

• Market size analysis for current congestive heart failure (CHF) treatment devices market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the congestive heart failure (CHF) treatment devices market.
• Various opportunities available for the other competitors in the congestive heart failure (CHF) treatment devices market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current congestive heart failure (CHF) treatment devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for congestive heart failure (CHF) treatment devices market growth in the coming future?

Target Audience who can be benefited from this Congestive Heart Failure (CHF) Treatment Devices Market Report Study

• Congestive heart failure (CHF) treatment device providers
• Research organizations and consulting companies
• Congestive heart failure (CHF) treatment devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in congestive heart failure (CHF) treatment devices
• Various end-users who want to know more about the congestive heart failure (CHF) treatment devices market and the latest technological developments in the congestive heart failure (CHF) treatment devices market.

Frequently Asked Questions for the Congestive Heart Failure (CHF) Treatment Devices Market:

1. What are congestive heart failure (CHF) treatment devices?

• The congestive heart failure (CHF) treatment devices involve a number of devices that maintain heart rhythms, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs) to treat CHF.

2. What is the market for congestive heart failure (CHF) treatment devices?

• The congestive heart failure (CHF) treatment devices market was valued at USD 17.41 billion in 2023, growing at a CAGR of 8.26% during the forecast period from 2024 to 2030 to reach USD 27.96 billion by 2030.

3. What are the drivers for the congestive heart failure (CHF) treatment devices market?

• The congestive heart failure (CHF) treatment devices market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), innovative product developmental activities by regulatory bodies, and the rising geriatric population that are expected to escalate the overall growth of the congestive heart failure (CHF) treatment devices market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the congestive heart failure (CHF) treatment devices market?

• Some of the key market players operating in the congestive heart failure (CHF) treatment devices market include GE HealthCare, Boston Scientific Corporation, Medtronic, Abbott, Inc., Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.

5. Which region has the highest share in the congestive heart failure (CHF) treatment devices market?

• North America is expected to dominate the overall congestive heart failure (CHF) treatment devices market during the forecast period from 2024 to 2030. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the congestive heart failure (CHF) treatment devices market in the North America region during the forecast period from 2024 to 2030.